

# Neal R Swerdlow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2256177/publications.pdf>

Version: 2024-02-01

137  
papers

9,657  
citations

71102

41  
h-index

40979

93  
g-index

138  
all docs

138  
docs citations

138  
times ranked

6916  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. <i>Psychopharmacology</i> , 2001, 156, 234-258.	3.1	1,562
2	Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. <i>Psychopharmacology</i> , 2001, 156, 117-154.	3.1	1,404
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
4	Realistic expectations of prepulse inhibition in translational models for schizophrenia research. <i>Psychopharmacology</i> , 2008, 199, 331-388.	3.1	479
5	Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients. <i>Biological Psychiatry</i> , 2006, 60, 1231-1240.	1.3	384
6	Startle Gating Deficits in a Large Cohort of Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 2006, 63, 1325-35.	12.3	305
7	Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 37.	11.0	163
8	Cross-species Studies of Sensorimotor Gating of the Startle Reflex. <i>Annals of the New York Academy of Sciences</i> , 1999, 877, 202-216.	3.8	160
9	Hierarchical Organization of Gamma and Theta Oscillatory Dynamics in Schizophrenia. <i>Biological Psychiatry</i> , 2012, 71, 873-880.	1.3	160
10	Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. <i>Journal of Psychopharmacology</i> , 2016, 30, 1072-1081.	4.0	159
11	Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. <i>Schizophrenia Research</i> , 2015, 163, 63-72.	2.0	154
12	The Functional Output of the Mesolimbic Dopamine System. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 216-227.	3.8	133
13	Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2015, 1344, 105-119.	3.8	119
14	Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. <i>Schizophrenia Research</i> , 2014, 152, 503-512.	2.0	91
15	The utility of P300 as a schizophrenia endophenotype and predictive biomarker: Clinical and socio-demographic modulators in COGS-2. <i>Schizophrenia Research</i> , 2015, 163, 53-62.	2.0	87
16	Discrepant Findings of Clozapine Effects on Prepulse Inhibition of Startle: Is It the Route or the Rat?. <i>Neuropsychopharmacology</i> , 1998, 18, 50-56.	5.4	86
17	Amphetamine Effects on Prepulse Inhibition Across-Species: Replication and Parametric Extension. <i>Neuropsychopharmacology</i> , 2003, 28, 640-650.	5.4	80
18	Anticholinergic Medication Burdenâ€‘Associated Cognitive Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2021, 178, 838-847.	7.2	80

#	ARTICLE	IF	CITATIONS
19	Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. <i>JAMA Psychiatry</i> , 2019, 76, 1274.	11.0	78
20	Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis. <i>Neuropsychopharmacology</i> , 2016, 41, 419-430.	5.4	77
21	Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. <i>Neuropsychopharmacology</i> , 2017, 42, 2206-2213.	5.4	73
22	Are we studying and treating schizophrenia correctly?. <i>Schizophrenia Research</i> , 2011, 130, 1-10.	2.0	71
23	Effects of D3/D2 Dopamine Receptor Agonists and Antagonists on Prepulse Inhibition of Acoustic Startle in the Rat. <i>Neuropsychopharmacology</i> , 1995, 12, 139-145.	5.4	70
24	Effects of Sustained Phencyclidine Exposure on Sensorimotor Gating of Startle in Rats. <i>Neuropsychopharmacology</i> , 1999, 21, 28-39.	5.4	67
25	Antipsychotic Effects on Prepulse Inhibition in Normal "Low Gating" Humans and Rats. <i>Neuropsychopharmacology</i> , 2006, 31, 2011-2021.	5.4	66
26	Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. <i>Schizophrenia Research</i> , 2016, 170, 30-40.	2.0	65
27	Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. <i>Psychopharmacology</i> , 2003, 169, 314-320.	3.1	63
28	Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). <i>Schizophrenia Research</i> , 2015, 163, 38-46.	2.0	62
29	Multi-site studies of acoustic startle and prepulse inhibition in humans: Initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. <i>Schizophrenia Research</i> , 2007, 92, 237-251.	2.0	61
30	Update: Studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1150-1156.	6.1	58
31	Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 562-568.	1.5	57
32	Heritable differences in the dopaminergic regulation of sensorimotor gating. <i>Psychopharmacology</i> , 2004, 174, 452-462.	3.1	55
33	Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2017, 42, 2633-2639.	5.4	55
34	Using animal models to develop therapeutics for Tourette Syndrome. , 2005, 108, 281-293.		54
35	Convergence and Divergence in the Neurochemical Regulation of Prepulse Inhibition of Startle and N40 Suppression in Rats. <i>Neuropsychopharmacology</i> , 2006, 31, 506-515.	5.4	54
36	Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). <i>Schizophrenia Research</i> , 2015, 163, 73-79.	2.0	52

#	ARTICLE	IF	CITATIONS
37	Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. <i>Schizophrenia Research</i> , 2018, 198, 6-15.	2.0	52
38	Treat and Teach Our Students Well: College Mental Health and Collaborative Campus Communities. <i>Psychiatric Services</i> , 2016, 67, 957-963.	2.0	51
39	Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of schizophrenia research. <i>Schizophrenia Research</i> , 2015, 163, 9-16.	2.0	47
40	Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 606-612.	5.4	47
41	Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 373-385.	4.3	46
42	Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant?. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 305-325.	1.7	45
43	Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. <i>Psychopharmacology</i> , 2016, 233, 3513-3525.	3.1	45
44	Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome. <i>Psychopharmacology</i> , 2006, 186, 246-254.	3.1	44
45	Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. <i>American Journal of Psychiatry</i> , 2016, 173, 385-391.	7.2	42
46	Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 77, 291-302.	2.9	40
47	Early and Late Effects of Sustained Haloperidol on Apomorphine- and Phencyclidine-induced Sensorimotor Gating Deficits. <i>Neuropsychopharmacology</i> , 2000, 23, 517-527.	5.4	38
48	Heritable differences in the dopaminergic regulation of sensorimotor gating. <i>Psychopharmacology</i> , 2004, 174, 441-451.	3.1	36
49	Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 80, 203-211.	2.9	36
50	Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. <i>Schizophrenia Research</i> , 2018, 202, 378-384.	2.0	36
51	Integrative Circuit Models and Their Implications for the Pathophysiologies and Treatments of the Schizophrenias. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, 555-583.	1.7	35
52	Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia. <i>Translational Psychiatry</i> , 2020, 10, 405.	4.8	35
53	Preclinical models relevant to Tourette syndrome. <i>Advances in Neurology</i> , 2006, 99, 69-88.	0.8	35
54	Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the Pacific Rim. <i>Psychiatric Genetics</i> , 2005, 15, 61-65.	1.1	34

#	ARTICLE	IF	CITATIONS
55	Comparison of the Heritability of Schizophrenia and Endophenotypes in the COGS-1 Family Study. <i>Schizophrenia Bulletin</i> , 2014, 40, 1404-1411.	4.3	34
56	Effects of discrete acoustic prestimuli on perceived intensity and behavioral responses to startling acoustic and tactile stimuli. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 1999, 27, 547-556.	1.3	34
57	Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. <i>Schizophrenia Research</i> , 2018, 199, 285-291.	2.0	33
58	Sensorimotor gating deficits in schizophrenia: Advancing our understanding of the phenotype, its neural circuitry and genetic substrates. <i>Schizophrenia Research</i> , 2018, 198, 1-5.	2.0	33
59	Prepulse inhibition of perceived stimulus intensity: paradigm assessment. <i>Biological Psychology</i> , 2005, 69, 133-147.	2.2	31
60	Beyond Antipsychotics: Pharmacologically-Augmented Cognitive Therapies (PACTs) for Schizophrenia. <i>Neuropsychopharmacology</i> , 2012, 37, 310-311.	5.4	31
61	Regulation of Sensorimotor Gating of the Startle Reflex by Serotonin 2A Receptors Ontogeny and Strain Differences. <i>Neuropsychopharmacology</i> , 2000, 23, 623-632.	5.4	30
62	Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rat strains. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 75, 191-197.	2.9	30
63	Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 87, 1-10.	2.9	30
64	A distributed frontotemporal network underlies gamma-band synchronization impairments in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2020, 45, 2198-2206.	5.4	29
65	Sensory and Sensorimotor Gating Deficits after Neonatal Ventral Hippocampal Lesions in Rats. <i>Developmental Neuroscience</i> , 2012, 34, 240-249.	2.0	28
66	Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) Study: The moderating role of smoking status and antipsychotic medications. <i>Schizophrenia Research</i> , 2015, 163, 24-31.	2.0	26
67	Prestimulus modification of the startle reflex: relationship to personality and physiological markers of dopamine function. <i>Biological Psychology</i> , 2003, 62, 17-26.	2.2	25
68	Weak prepulses inhibit but do not elicit startle in rats and humans. <i>Biological Psychiatry</i> , 2004, 55, 1195-1198.	1.3	25
69	Forebrain D1 function and sensorimotor gating in rats: Effects of D1 blockade, frontal lesions and dopamine denervation. <i>Neuroscience Letters</i> , 2006, 402, 40-45.	2.1	25
70	Unique contributions of sensory discrimination and gamma synchronization deficits to cognitive, clinical, and psychosocial functional impairments in schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 280-287.	2.0	25
71	Effects of prepulse intensity, duration, and bandwidth on perceived intensity of startling acoustic stimuli. <i>Biological Psychology</i> , 2007, 74, 389-395.	2.2	24
72	Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 123-130.	2.0	24

#	ARTICLE	IF	CITATIONS
73	Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. <i>Psychopharmacology</i> , 2016, 233, 2399-2410.	3.1	23
74	Sensitivity to Sensorimotor Gating-Disruptive Effects of Apomorphine in two Outbred Parental Rat Strains and their F1 and N2 Progeny. <i>Neuropsychopharmacology</i> , 2003, 28, 226-234.	5.4	22
75	Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. <i>Schizophrenia Research</i> , 2005, 72, 169-183.	2.0	22
76	A novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 88, 280-290.	2.9	22
77	Reduced startle gating after D1 blockade: Effects of concurrent D2 blockade. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 82, 293-299.	2.9	21
78	Pramipexole effects on startle gating in rats and normal men. <i>Psychopharmacology</i> , 2009, 205, 689-698.	3.1	21
79	Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. <i>Psychopharmacology</i> , 2012, 224, 349-362.	3.1	21
80	Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults. <i>Psychopharmacology</i> , 2013, 227, 165-176.	3.1	21
81	The Auditory Brain-Stem Response to Complex Sounds: A Potential Biomarker for Guiding Treatment of Psychosis. <i>Frontiers in Psychiatry</i> , 2014, 5, 142.	2.6	21
82	Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2016, 43, sbw148.	4.3	21
83	Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients. <i>Schizophrenia Research</i> , 2019, 208, 384-389.	2.0	21
84	Nonlinear dynamics underlying sensory processing dysfunction in schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3847-3852.	7.1	21
85	The effects of age and sex on cognitive impairment in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS) study. <i>PLoS ONE</i> , 2020, 15, e0232855.	2.5	21
86	Serotonin, obsessive compulsive disorder and the basal ganglia. <i>International Review of Psychiatry</i> , 1995, 7, 115-129.	2.8	20
87	Memantine effects on auditory discrimination and training in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2020, 45, 2180-2188.	5.4	20
88	Electrophysiological biomarkers of behavioral dimensions from cross-species paradigms. <i>Translational Psychiatry</i> , 2021, 11, 482.	4.8	20
89	Startle gating in rats is disrupted by chemical inactivation but not D2 stimulation of the dorsomedial thalamus. <i>Brain Research</i> , 2002, 953, 246-254.	2.2	18
90	Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 979-987.	2.1	18

#	ARTICLE	IF	CITATIONS
91	Selection criteria for neurophysiologic biomarkers to accelerate the pace of CNS therapeutic development. <i>Neuropsychopharmacology</i> , 2020, 45, 237-238.	5.4	17
92	Neural network dynamics underlying gamma synchronization deficits in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110224.	4.8	17
93	Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. <i>Neuropharmacology</i> , 2013, 75, 38-46.	4.1	16
94	Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. <i>Behavioural Brain Research</i> , 2013, 257, 118-128.	2.2	16
95	Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. <i>Schizophrenia Research</i> , 2015, 163, 47-52.	2.0	16
96	Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 581-590.	1.5	16
97	Genetic differences in startle gating-disruptive effects of apomorphine: Evidence for central mediation.. <i>Behavioral Neuroscience</i> , 2002, 116, 682-690.	1.2	16
98	Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2018, 43, 708-717.	5.4	15
99	Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment. <i>Psychopharmacology</i> , 2020, 237, 1959-1972.	3.1	14
100	Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. <i>Schizophrenia Research</i> , 2016, 174, 1-9.	2.0	13
101	Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 215, 97-104.	2.0	13
102	Amphetamine alters an EEG marker of reward processing in humans and mice. <i>Psychopharmacology</i> , 2022, 239, 923-933.	3.1	13
103	California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: Comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). <i>Schizophrenia Research</i> , 2015, 163, 32-37.	2.0	12
104	Abnormal Effective Connectivity Underlying Auditory Mismatch Negativity Impairments in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 1028-1039.	1.5	11
105	Is There an Association between Advanced Paternal Age and Endophenotype Deficit Levels in Schizophrenia?. <i>PLoS ONE</i> , 2014, 9, e88379.	2.5	11
106	Prestimulus effects on startle magnitude: Sensory or motor?. <i>Behavioral Neuroscience</i> , 2002, 116, 672-681.	1.2	10
107	Neuropsychology of schizophrenia: The "hole" thing is wrong. <i>Behavioral and Brain Sciences</i> , 1991, 14, 51-53.	0.7	9
108	Probing the molecular basis for an inherited sensitivity to the startle-gating disruptive effects of apomorphine in rats. <i>Psychopharmacology</i> , 2011, 216, 401-410.	3.1	9

#	ARTICLE	IF	CITATIONS
109	Bending the curve on psychosis outcomes. <i>Lancet Psychiatry</i> , 2015, 2, 365-367.	7.4	9
110	Central auditory processing deficits in schizophrenia: Effects of auditory-based cognitive training. <i>Schizophrenia Research</i> , 2021, 236, 135-141.	2.0	9
111	Toward a unified hypothesis of cortico-striato-pallido-thalamus function?. <i>Behavioral and Brain Sciences</i> , 1990, 13, 172-177.	0.7	8
112	Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia. <i>Schizophrenia Research</i> , 2019, 210, 215-220.	2.0	8
113	Detecting the Inverted-U in fMRI Studies of Schizophrenia: A Comparison of Three Analysis Methods. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 258-269.	1.8	7
114	The viability of the frequency following response characteristics for use as biomarkers of cognitive therapeutics in schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 372-382.	2.0	7
115	Tourette syndrome: Current controversies and the battlefield landscape. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 329-331.	4.2	6
116	124. Experimental Medicine Approaches to Leveraging Auditory Information Processing Neuroplasticity Toward Therapeutic Development in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S69-S69.	4.3	6
117	EEG reveals that dextroamphetamine improves cognitive control through multiple processes in healthy participants. <i>Neuropsychopharmacology</i> , 2022, 47, 1029-1036.	5.4	6
118	Auditory-Based Cognitive Training Drives Short- and Long-Term Plasticity in Cortical Networks in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	5
119	Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 106, 128-131.	2.9	4
120	Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients. <i>Neuropsychopharmacology</i> , 2019, 44, 2277-2284.	5.4	4
121	Evaluation of the frequency following response as a predictive biomarker of response to cognitive training in schizophrenia. <i>Psychiatry Research</i> , 2021, 305, 114239.	3.3	4
122	Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2015, 15, 901-914.	2.0	3
123	Heritability of acoustic startle magnitude and latency from the consortium on the genetics of schizophrenia. <i>Schizophrenia Research</i> , 2020, 224, 33-39.	2.0	3
124	Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1431-1438.	2.6	3
125	Behavioral neurobiology of schizophrenia and its treatment. Preface. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 4, v-vii.	1.7	3
126	Don't leave the "off" consciousness. <i>Behavioral and Brain Sciences</i> , 1995, 18, 699-700.	0.7	2



#	ARTICLE	IF	CITATIONS
127	Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. <i>Psychiatry Research</i> , 2014, 219, 67-71.	3.3	2
128	Click-evoked auditory brainstem responses (ABRs) are intact in schizophrenia and not sensitive to cognitive training. <i>Biomarkers in Neuropsychiatry</i> , 2022, 6, 100046.	1.0	2
129	Reawakening research on reducing shock pain. <i>Heart Rhythm</i> , 2016, 13, 1149-1150.	0.7	1
130	Commentary: Lessons Learned From Animal Models for Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 20-22.	1.2	1
131	Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course. <i>Psychological Medicine</i> , 2023, 53, 140-148.	4.5	1
132	Effects of the first prepulse on the blink response to a startling noise.. <i>Behavioral Neuroscience</i> , 2009, 123, 607-613.	1.2	1
133	In Memorium: Professor David S Segal. <i>Neuropsychopharmacology</i> , 2006, 31, 2331-2331.	5.4	0
134	Title is missing!. , 2020, 15, e0232855.		0
135	Title is missing!. , 2020, 15, e0232855.		0
136	Title is missing!. , 2020, 15, e0232855.		0
137	Title is missing!. , 2020, 15, e0232855.		0